SHS has raised €90M in the first closing of its fifth fund dedicated to companies in life sciences and medtech.
SHS, based in Tübingen, is aiming to raise a total of €150M for its fifth fund. In this first closing, around half of the €90M raised came from existing investors including professional pension insurers and family offices.
SHS plans to invest in between 12 to 15 companies and up to €30M per company. With this new fund, SHS plans to expand its current focus on German, Austrian and Swiss companies to invest in firms from Scandinavia and the Benelux countries as well. Its previous funds invested in companies such as EIT, an orthopedic bioprinting specialist; German neurovascular disease med-tech phenox; and SIS Medical, a Swiss company specializing in cardiology products.
This year, we’ve seen closings and launches of other noteworthy medtech funds. In March, BioMedPartners raised €86M to invest in Swiss, German and other EU biotechs. A month later, Sofinnova partners launched a €275M crossover fund to support medtech companies from early to late stage.
Image by ADcour/Shutterstock